AI Analysis | Feedback

Here are 1-3 brief analogies for Apellis Pharmaceuticals:

1. Apellis Pharmaceuticals is like a specialized Alexion Pharmaceuticals, pioneering next-generation drugs that inhibit the complement system to treat a variety of autoimmune and inflammatory diseases.
2. Think of Apellis as a biotech company aiming to be for the complement system what AbbVie is for TNF alpha, developing therapies for a wide range of inflammatory and rare diseases.

AI Analysis | Feedback

• Pegcetacoplan (marketed as EMPAVELI): A C3 inhibitor, it is the company's lead therapeutic compound in development for various autoimmune and inflammatory diseases, including geographic atrophy, paroxysmal nocturnal hemoglobinuria, and other rare conditions.
• APL-2006: A bispecific C3 and VEGF inhibitor aimed at treating complement-mediated disorders.
• APL-1030: A C3 inhibitor under development for the treatment of multiple neurodegenerative diseases.
• Combination of EMPAVELI and siRNA: A development program focused on combining EMPAVELI with a small interfering RNA (siRNA) to reduce the liver's production of C3 proteins.

AI Analysis | Feedback

Apellis Pharmaceuticals (APLS) - Major Customers

As a commercial-stage biopharmaceutical company focused on developing and commercializing prescription drugs for serious medical conditions, Apellis Pharmaceuticals primarily sells its products to companies within the healthcare supply chain rather than directly to individuals. Its major customers are typically large pharmaceutical wholesalers that handle the distribution of drugs to hospitals, clinics, and pharmacies across the healthcare system. While the provided background information does not explicitly name Apellis' specific customers, the following are generally considered the major pharmaceutical wholesalers in the United States, through which a company like Apellis would typically distribute its products:

• McKesson Corporation (MCK)
• AmerisourceBergen Corporation (ABC)
• Cardinal Health, Inc. (CAH)

AI Analysis | Feedback

AI Analysis | Feedback

Cedric Francois, MD, PhD Co-Founder & Chief Executive Officer/President
Cedric Francois co-founded Apellis Pharmaceuticals in 2009. Before Apellis, he co-founded Potentia Pharmaceuticals, Inc. in 2001 and served as its President and CEO. Potentia Pharmaceuticals was acquired by Alcon Research Ltd in 2009. He holds an MD from the University of Leuven in Belgium and a PhD in physiology from the University of Louisville. He was also a member of the research team that performed the first successful hand transplantation.

Timothy Sullivan Chief Financial Officer
Timothy Sullivan became Chief Financial Officer of Apellis in October 2017. From 2014 to 2017, he was a Partner at Aju IB Investment, a venture capital firm, where he led investments in life sciences companies. Prior to that, he was Managing Director and Head of Life Sciences Investment Banking at RBS Citizens from 2011 to 2014. He has served on the boards of directors for G1 Therapeutics, Inc. and Molecular Templates, Inc. He was an observer on Apellis' board of directors from 2014 until joining as CFO. He earned his MBA from Columbia Business School and his BA in biology from Harvard University.

Pascal Deschatelets, PhD Co-Founder & Chief Scientific Officer
Pascal Deschatelets co-founded Apellis Pharmaceuticals in 2009. He previously co-founded Potentia Pharmaceuticals, where he was Chief Operating Officer when the company's ocular drug development program was licensed to Alcon in 2009. Apellis later acquired all of Potentia's assets in 2015. He also co-founded Syntetica Fine Chemicals, a custom chemical synthesis company. He holds a PhD in Organic Chemistry from the University of Montreal and completed postdoctoral training at Harvard University.

Caroline Baumal, MD Chief Medical Officer
Caroline Baumal joined Apellis as Chief Medical Officer in January 2023. She is a leading retina specialist with over 25 years of experience in retina research and patient care. Dr. Baumal serves as a professor of ophthalmology at New England Eye Center, Tufts Medical Center, specializing in diseases and surgery of the retina and vitreous. A board-certified ophthalmologist, she has authored over 170 publications and received numerous awards. She received her M.D. from the University of Toronto and completed her ophthalmology residency and two fellowships.

Leslie Meltzer, PhD Chief Research & Development Officer
Leslie Meltzer joined Apellis in 2025 as Chief Research & Development Officer. She possesses a proven track record of advancing therapies from discovery through regulatory approvals and commercialization, with deep expertise in rare disease and cell and gene therapies, and has contributed to the successful launches of seven medicines. Before joining Apellis, she was Chief Medical Officer at Orchard Therapeutics, where she led Development, Medical Affairs, Regulatory Affairs, Diagnostics, and Patient Advocacy functions, playing a pivotal role in securing global regulatory approvals. Her prior experience includes senior leadership positions at Keryx Biopharmaceuticals, Biogen, and Actelion Pharmaceuticals. She holds a Ph.D. in neuroscience from Stanford University.

AI Analysis | Feedback

The key risks to Apellis Pharmaceuticals (APLS) primarily revolve around the commercialization and safety profile of its lead product, Syfovre, alongside the inherent challenges of clinical development and market competition for its pipeline.

1. Safety Concerns and Commercialization Challenges for Syfovre (pegcetacoplan for geographic atrophy)

   Apellis Pharmaceuticals faces significant risks related to the safety profile and subsequent commercial adoption of Syfovre, its treatment for geographic atrophy (GA). Following its FDA approval in February 2023, reports emerged of rare but serious adverse events, including retinal vasculitis and intraocular inflammation, in patients receiving Syfovre injections. The American Society of Retina Specialists (ASRS) issued a warning to doctors in July 2023, which led to a substantial decline in Apellis' share price. In November 2023, Apellis issued an Important Drug Warning, updating the US Prescribing Information to include retinal vasculitis as a potential health risk, in collaboration with the FDA. Although the estimated rate of these events is low (approximately 0.01% per injection), the potential for severe vision loss or permanent blindness makes this a critical risk that can impact physician prescribing habits, patient confidence, and the drug's overall market uptake, despite Syfovre holding a leading market share in GA. Furthermore, the European Medicines Agency (EMA) has repeatedly declined to endorse Apellis' marketing authorization application for Syfovre in the EU.

2. Clinical Trial Outcomes and Regulatory Approval for Pipeline Candidates

   A substantial portion of Apellis' future growth and value is tied to the successful advancement and regulatory approval of its pipeline candidates. While its lead product candidate, pegcetacoplan, is in Phase III clinical trials for geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), and EMPAVELI (systemic pegcetacoplan) is being developed for numerous other indications like cold agglutinin disease (CAD), hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), C3 glomerulopathy (C3G), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and amyotrophic lateral sclerosis (ALS), there is no guarantee of success. For example, Apellis and its partner Sobi discontinued the development of systemic pegcetacoplan for ALS due to a lack of efficacy in the mid-stage MERIDIAN study. The company is also advancing pivotal trials for EMPAVELI in FSGS and DGF and initiating a Phase 2 study for a next-generation therapy for retinal diseases. Failure to meet primary endpoints in these trials, unexpected adverse events, or delays in gaining regulatory approvals would significantly impede the company's ability to expand its revenue streams and market presence.

3. Intense Competition and Evolving Market Dynamics

   Apellis operates in highly competitive biopharmaceutical markets, particularly for complement-driven diseases. In the geographic atrophy (GA) market, where Syfovre has a significant market share, it faces direct competition from other approved treatments such as Astellas' Izervay, and broader competition from Regeneron's Eylea and Roche's Vabysmo. The competitive landscape is further intensified by emerging treatments, including a pozelimab/cemdisiran combination being developed by Regeneron and Alnylam, with Phase 3 data expected in late 2027. EMPAVELI also faces competition in the hematology sector for PNH and other rare disease indications. Apellis' ability to maintain its market share, differentiate its treatments, and adapt to competitor innovation and strategic alliances is crucial for its sustained success.

AI Analysis | Feedback

null

AI Analysis | Feedback

Addressable Markets for Apellis Pharmaceuticals' Main Products:

• Geographic Atrophy (GA) in Age-Related Macular Degeneration: The global market for geographic atrophy treatment was valued at approximately USD 1.78 billion in 2024 and is projected to reach USD 3.80 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 9.60% during the forecast period. Another estimate puts the global market at USD 2.11 billion in 2025, increasing to USD 2.4 billion in 2026, and projected to reach USD 3.92 billion by 2030.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): The global paroxysmal nocturnal hemoglobinuria treatment market was estimated at USD 5.75 billion in 2024 and is projected to reach USD 9.96 billion by 2030, growing at a CAGR of 9.6% from 2025 to 2030. Other estimates show the global market at USD 5 billion in 2025, projected to reach USD 13.94 billion by 2035 with a CAGR of 10.8%. The market in the 7 Major Markets (7MM – US, EU4, UK, Japan) is expected to grow from USD 1,554 million in 2025 to USD 2,883 million in 2034.
• Cold Agglutinin Disease (CAD): The global cold agglutinin disease drugs market was valued at USD 312.4 million in 2024 and is projected to reach USD 502.6 million by 2032, with a CAGR of 6.8%. The U.S. market alone was estimated at USD 128.6 million in 2024. The 7 Major Markets (7MM) for CAD reached USD 220.8 million in 2024 and are expected to reach USD 1,104.8 million by 2035.
• Amyotrophic Lateral Sclerosis (ALS): The global amyotrophic lateral sclerosis market size was valued at USD 0.79 billion in 2024 and is estimated to reach USD 1.38 billion by 2035, representing a CAGR of 5.2%. Another report valued the global market at USD 0.89 billion in 2025, projected to grow to USD 2.19 billion by 2034, exhibiting a CAGR of 9.93%. In 2023, the ALS market size in the 7 Major Markets (7MM) was approximately USD 1,000 million, with the US market alone estimated at approximately USD 920 million.
• C3 Glomerulopathy (C3G): The market for C3 Glomerulopathy across the 7 Major Markets (US, EU4, UK, and Japan) reached a value of USD 9.3 billion in 2024 and is expected to reach USD 12.5 billion by 2035, growing at a CAGR of 2.75%. The global C3 Glomerulopathy market size was estimated at USD 2.19 billion in 2024 and is predicted to grow to USD 4.44 billion by 2035.
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): The market size for IC-MPGN in the United States was approximately USD 12 million in 2023 and is expected to increase by 2034. The IC-MPGN market size in the 7 Major Markets (7MM) was approximately USD 17 million in 2023, with a significant increase projected by 2034, driven by the introduction of emerging therapies like pegcetacoplan.

AI Analysis | Feedback

• Growing Adoption and Market Leadership of SYFOVRE for Geographic Atrophy (GA): SYFOVRE (pegcetacoplan injection) is anticipated to continue its strong growth trajectory in the geographic atrophy market. The company has consistently reported increasing injection volumes, reflecting robust underlying demand and its sustained market leadership with approximately 60% market share in GA. Future enhancements, such as the planned regulatory submission for a SYFOVRE prefilled syringe in the first half of 2026, are expected to further reduce workflow friction and enhance convenience, driving continued market penetration.
• Expanded Indications and Uptake of EMPAVELI in Rare Kidney Diseases (C3G and IC-MPGN): EMPAVELI (pegcetacoplan) is expected to be a significant revenue driver following its FDA approval in July 2025 for C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). This approval is set to unlock a substantial addressable market, estimated to serve between 5,000 to 8,000 patients across the U.S. and EU, where no prior therapeutic options were available. The launch has shown "great momentum" and early traction, with analysts tracking its performance ahead of nephrology benchmarks.
• Advancement of EMPAVELI into Additional Nephrology Indications: Beyond its approved indications, Apellis is actively expanding the clinical development of EMPAVELI for other rare kidney diseases. The company is on track to initiate pivotal Phase 3 trials for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) in the second half of 2025. Successful progression and potential approvals in these areas within the next 2-3 years could significantly broaden EMPAVELI's market reach and contribute to further revenue growth.
• Strategic Pipeline Development and Innovative Therapies: Apellis's ongoing investment in its C3 complement platform and a differentiated pipeline is a long-term growth driver, with some programs potentially impacting revenue within the next few years. The company plans to move into the clinic in the second half of 2026 with its first gene-editing program for the FcRn class, developed in collaboration with Beam Therapeutics, which could offer a "once-and-done treatment" for complement-driven diseases. These innovative approaches aim to continuously generate new product candidates and expand into new therapeutic areas.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Issuance

• Apellis Pharmaceuticals has consistently increased its number of shares outstanding over the last few years, indicating share issuances to raise capital.
• The number of shares outstanding grew from approximately 85.66 million at the end of 2021 to about 126.42 million by the end of 2025.

Inbound Investments

• In October 2020, Apellis received an upfront payment of $250 million from Swedish Orphan Biovitrum (Sobi) as part of a strategic collaboration for systemic pegcetacoplan, with eligibility for up to $915 million in milestone payments and $80 million in R&D reimbursement over four years.
• In July 2025, Apellis entered a royalty purchase agreement with Sobi, securing an upfront sum of $275 million and potentially up to an additional $25 million in milestone payments, in exchange for 90% of its future ex-U.S. royalties for Aspaveli.

Outbound Investments

• In June 2021, Apellis made an upfront payment totaling $75 million to Beam Therapeutics as part of an exclusive five-year research collaboration. This partnership focuses on utilizing Beam's base editing technology to discover new treatments for complement-driven diseases.

Capital Expenditures

• Capital expenditures have been relatively low for Apellis Pharmaceuticals, with recent figures indicating approximately -$313,000 in the last 12 months.
• In the most recent quarter, capital expenditures totaled around -$0.15 million.